PDCD1 and non-small cell lung carcinoma: Immunotherapy based on programmed death-1 (PD-1) has improved clinical outcomes in patients with nonsmall cell lung cancer (NSCLC), however, the efficiency of monotherapy remains low, resulting in increased number of trials of combined therapies, with encouraging results [5].